Atreca, Inc. (NASDAQ: BCEL) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17.
Atreca is a biopharma company that uses its platform to discover and develop antibody-based immunotherapies to treat a range of solid tumor types. Unlike the traditional oncology drug discovery approaches, Atreca uses human immune system to lead it to unique antibody-target pairs from patients experiencing a clinically meaningful active immune response against their tumors.
The company's lead product candidate ATRC-101 is a monoclonal antibody, which reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models.
Atreca generated a loss of $37.94 million in fiscal year 2018, wider than the loss of $27.53 million in the year-ago period. For the third quarter ended March 2019, the loss was $13.58 million.
The stock traded around $16.61 per share at time of publication.
Atreca IPO: What You Need To Know
FDA Approves Edesa's Dermatitis Treatment Study, Shares Up More Than 100%
See more from Benzinga
- FDA Approves Edesa's Dermatitis Study, Shares Up More Than 100%
- Pier 1 Imports' 1-for-20 Reverse Stock Split Takes Effect
- Jensyn Acquisition Shareholders OK Merger With Peck Electric
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.